{"id":715946,"date":"2024-10-08T14:14:01","date_gmt":"2024-10-08T14:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=715946"},"modified":"2024-10-08T14:14:01","modified_gmt":"2024-10-08T14:14:01","slug":"barretts-esophagus-treatment-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/barretts-esophagus-treatment-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight_715946.html","title":{"rendered":"Barrett&#8217;s Esophagus Treatment Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1728380320.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Barrett&#039;s Esophagus Treatment Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1728380320.jpeg\" alt=\"Barrett&#039;s Esophagus Treatment Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><em>Barrett&rsquo;s Esophagus Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Barrett&rsquo;s Esophagus Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s&nbsp;<strong>&ldquo;Barrett&rsquo;s Esophagus Market Insights, Epidemiology and Market Forecast &ndash; 2034&rdquo;&nbsp;<\/strong>report delivers an in-depth understanding of the Barrett&rsquo;s Esophagus, historical and forecasted epidemiology as well as the Barrett&rsquo;s Esophagus market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Unlock detailed insights into the Barrett&rsquo;s Esophagus Market by downloading the comprehensive report from DelveInsight @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/barett-esophagus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Barrett&rsquo;s Esophagus Treatment Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Barrett&rsquo;s Esophagus Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The growth in market size is directly influenced by the increasing awareness and diagnosis of Barrett&#8217;s esophagus across the 7MM.<\/li>\n<li>As per a study conducted in the US, the estimated prevalence of Barrett&#8217;s esophagus is up to 5.6% of the population, including asymptomatic patients. However, the prevalence can vary widely, from 0.4% to more than 20%, depending on the population and the criteria used for diagnosis.<\/li>\n<li>Research conducted by Bernal-Mendez et al. reported that 81 out of 420 patients with Barrett&#8217;s esophagus presented with some degree of dysplasia or cancer (11.4% with low-grade dysplasia, 4.8% with high-grade dysplasia, and 3.1% with esophageal cancer).<\/li>\n<li>A study from the UK by Blankenstein et al. (2018) revealed that the prevalence of Barrett&#8217;s esophagus rose with 7.4% for each additional year of age between the age of 20 and 59 year in males.<\/li>\n<li>The leading Barrett&#8217;s Esophagus Companies such as <strong><em>Interscope Inc., Lucid Diagnostics, Inc., Capsulomics Inc., CDx Diagnostics<\/em><\/strong>, and others.<\/li>\n<li>Promising Barrett&#8217;s Esophagus Therapies such as <strong><em>Ceclazepide<\/em><\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gain a competitive edge in the Barrett&#8217;s Esophagus Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/barett-esophagus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Barrett&#8217;s Esophagus Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Barrett&#8217;s Esophagus Epidemiology Segmentation in the 7MM<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Barrett&#8217;s Esophagus Prevalent Cases<\/li>\n<li>Total Barrett&#8217;s Esophagus Diagnosed Prevalent Cases<\/li>\n<li>Barrett&#8217;s Esophagus Gender-specific Diagnosed Prevalent Cases<\/li>\n<li>Barrett&#8217;s Esophagus Treated Cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Barrett&#8217;s Esophagus Treatment Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The current treatment of Barrett&#8217;s esophagus primarily aims to manage gastroesophageal reflux disease (GERD), reduce inflammation, and prevent progression to dysplasia or esophageal cancer. Treatment approaches can be divided into managing GERD, monitoring for dysplasia, and addressing dysplastic changes or early-stage cancer. Management of GERD Proton Pump Inhibitors (PPIs): These are the first-line medications for managing Barrett&rsquo;s esophagus by controlling GERD. PPIs, such as omeprazole or esomeprazole, reduce stomach acid production, which helps alleviate acid reflux, reduce inflammation, and promote healing of the esophagus. While PPIs do not reverse Barrett&#8217;s esophagus, they may reduce the risk of progression to cancer.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover key developments and opportunities in the Barrett&#8217;s Esophagus Market. Click here to learn more from DelveInsight&rsquo;s latest report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/barett-esophagus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Barrett&#8217;s Esophagus Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Barrett&#8217;s Esophagus Therapeutics Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The Barrett&rsquo;s esophagus market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including Trio Medicines, among others have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Barrett&rsquo;s Esophagus Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Ceclazepide: Trio Medicines<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Ceclazepide, also known as TR2-A, is a prodrug and a novel, potent, and highly selective gastrin\/CCK2 receptor antagonist indicated for the treatment of Barrett&#8217;s esophagus. The body efficiently converts TR2-A to the active molecule TR2 in the bloodstream. The patent application for ceclazepide was recently approved in Europe and the US. Currently, the drug is in the preclinical phase of clinical development, with no updates from the company since 2021.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Download DelveInsight&rsquo;s Barrett&#8217;s Esophagus Market report today and stay ahead in this rapidly evolving field. @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/barett-esophagus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Barrett&#8217;s Esophagus Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Barrett&#8217;s Esophagus Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- 7MM<\/li>\n<li>Barrett&#8217;s Esophagus Companies- Interscope Inc., Lucid Diagnostics, Inc., Capsulomics Inc., CDx Diagnostics, and others.<\/li>\n<li>Barrett&#8217;s Esophagus Therapies- Ceclazepide, and others.<\/li>\n<li>Barrett&#8217;s Esophagus Competitive Intelligence Analysis: SWOT analysis and Market entry strategies<\/li>\n<li>Barrett&#8217;s Esophagus Unmet Needs, KOL&#8217;s views, Analyst&#8217;s views, Barrett&#8217;s Esophagus Market Access and Reimbursement<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Barrett&#8217;s Esophagus Market Trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/barett-esophagus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Barrett&#8217;s Esophagus Market Trends<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Report Introduction<\/p>\n<p style=\"text-align: justify;\">3. Barrett&#8217;s Esophagus Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4 Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">5 Executive Summary<\/p>\n<p style=\"text-align: justify;\">6 Barrett&#8217;s Esophagus Key Events<\/p>\n<p style=\"text-align: justify;\">7 Disease Background and Overview: Barrett&#8217;s Esophagus<\/p>\n<p style=\"text-align: justify;\">8. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">9 Patient Journey<\/p>\n<p style=\"text-align: justify;\">10 Barrett&#8217;s Esophagus: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">11 Key Opinion Leaders&rsquo; Views<\/p>\n<p style=\"text-align: justify;\">12 Unmet Needs<\/p>\n<p style=\"text-align: justify;\">13 SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">14 Barrett&#8217;s Esophagus Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">15 Appendix<\/p>\n<p style=\"text-align: justify;\">16 DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">17 Disclaimer<\/p>\n<p style=\"text-align: justify;\">18 About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=barretts-esophagus-treatment-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=barretts-esophagus-treatment-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Barrett&rsquo;s Esophagus Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Barrett&rsquo;s Esophagus Therapeutics includes promising candidates that aim to not &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/barretts-esophagus-treatment-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight_715946.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-715946","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/715946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=715946"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/715946\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=715946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=715946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=715946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}